Advancements in Multiple Myeloma Treatment: Frontline Approaches and Therapies for Early Relapse : Episode 6
Clinical Experience in CAR-T-Cell Therapy in Early Relapsed MM and Insights From the CARTITUDE-4 Trial
Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy in early relapsed multiple myeloma can provide deep and durable responses for eligible patients, though patient selection, timing of referral, manufacturing logistics, and management of adverse effects remain important considerations in optimizing outcomes.
EP: 1.Current Strategies for Frontline Therapy in Transplant-Preferred NDMM
EP: 2.Brief Overview of PERSEUS, IsKia, and CASSIOPEIA Clinical Trials
EP: 3.Deciding Between Quadruplet and Triplet Therapy in Transplant-Preferred NDMM: Key Considerations
EP: 4.Insights of MAIA, BENEFIT, and IMROZ Trials on Frontline Treatment for Transplant Not-Preferred NDMM
EP: 5.Initial Impressions of the CEPHEUS Clinical Trial in Transplant Not-Preferred NDMM
Now Viewing
EP: 6.Clinical Experience in CAR-T-Cell Therapy in Early Relapsed MM and Insights From the CARTITUDE-4 Trial
Video content above is prompted by the following:
- What has been your experience with using CAR T-cell therapy in patients with early relapsed multiple myeloma?
- How does CAR T-cell therapy compare with other available second-line treatments?
Recent Videos
Related Content
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025Article
During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
